Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 110Gastrointestinal 26Lymphoid 10Genitourinary 7Thoracic 4Other hematologic neoplasm 3Gynecologic 3Sarcoma 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Dermatologic 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Epirubicin × Other solid neoplasm × Clear all
NCT00017186 2016-12-07

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Alliance for Clinical Trials in Oncology

Phase 2 Completed
69 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡